Pierre Fabre Pharma Canada is part of the Pierre Fabre group, the third largest French pharmaceutical company which has made its Research & Development a key element for its differentiation and a driving force for its growth in the medical field.

Based on a very active partnership policy, the Pierre Fabre Group concentrates its resources on research and development of original molecules, whether natural, chemical or biological for therapeutic uses.

With the focus on efficiency and productivity, the research conducted within the Pierre Fabre Laboratories concentrates on 5 strategic areas:

• oncology
• central nervous system
• cardio-vascular diseases
• immunology applied to the prevention of infectious diseases and anti-cancer therapy
• dermatology

Pierre Fabre key figures:

• 9310 employees worldwide (1317 in R&D)
• Worldwide sales in 2004: 1.75 Billion US$
• Pharmaceutical R&D Investments: 23% of sale
  • 50 % of R&D investments are dedicated to Oncology
• 14 Research and Development Center
• 22 products in R&D
• 34 marketed drugs.

Click here to close this window
and return to the Dermatology Update Sponsors Page.